down arrow

Lineage Cell Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US53566P1093
USD
1.74
0.06 (3.57%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.631.75

52 Week

0.372.09
Valuation
Technical
Day's Volume

CASH

57.51 k

Shareholding (Mar 2025)

FII

1.25%

Held by 29 FIIs

DII

87.93%

Held by 24 DIIs

Promoter

0.00%

How big is Lineage Cell Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Lineage Cell Therapeutics, Inc. has a market capitalization of 196.02 million, with net sales of 9.56 million and a net profit of -16.16 million over the latest four quarters. The company reported shareholder's funds of 78.38 million and total assets of 113.22 million as of Dec 24.

Market Cap: As of Jun 18, Lineage Cell Therapeutics, Inc. has a market capitalization of 196.02 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Lineage Cell Therapeutics reported net sales of 9.56 million and a net profit of -16.16 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 78.38 million and total assets of 113.22 million.

Read More

What does Lineage Cell Therapeutics, Inc. do?

22-Jun-2025

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for age-related degenerative diseases and serious medical conditions. As of March 2025, it has a market cap of $196.02 million, with net sales of $2 million and a net loss of $4 million.

Overview: <BR>Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for age-related degenerative diseases and other serious medical conditions, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 196.02 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.59 <BR>Return on Equity: -26.06% <BR>Price to Book: 2.48<BR><BR>Contact Details: <BR>Address: 2173 Salk Ave Ste 200, CARLSBAD CA: 92008-7354 <BR>Tel: 1 510 5213390 <BR>Fax: 1 510 5213389 <BR>Website: http://www.biotimeinc.com/

Read More

Who are in the management team of Lineage Cell Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Lineage Cell Therapeutics, Inc. includes Chairman Alfred Kingsley, CEO Brian Culley, and several independent directors: Deborah Andrews, Don Bailey, Neal Bradsher, Stephen Farrell, and Michael Mulroy. This team combines executive leadership with independent governance.

As of March 2022, the management team of Lineage Cell Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Alfred Kingsley, Chairman of the Board<BR>- Mr. Brian Culley, Chief Executive Officer, Interim Chief Financial Officer, and Director<BR>- Ms. Deborah Andrews, Independent Director<BR>- Mr. Don Bailey, Independent Director<BR>- Mr. Neal Bradsher, Independent Director<BR>- Mr. Stephen Farrell, Independent Director<BR>- Mr. Michael Mulroy, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors contributing to the governance of the company.

Read More

Is Lineage Cell Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

Lineage Cell Therapeutics, Inc. is currently considered risky and overvalued due to its negative P/E ratio, poor returns on capital, and high EV to Sales ratio, despite impressive year-to-date stock returns that raise concerns about long-term sustainability.

As of 12 August 2021, the valuation grade for Lineage Cell Therapeutics, Inc. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, particularly given its negative P/E ratio and poor returns on capital, with a Price to Book Value of 1.95, EV to Sales of 11.24, and ROE of -26.06%. <BR><BR>In comparison to peers, Lineage Cell Therapeutics has a significantly higher EV to EBITDA ratio of -5.19 compared to Poseida Therapeutics, Inc. at -13.3266 and Verastem, Inc. at -3.5165, suggesting it is less efficient in generating earnings relative to its enterprise value. Additionally, while the company has shown impressive stock returns year-to-date at 208.46%, outperforming the S&P 500's 12.22%, its long-term performance over 3 years and 5 years is lackluster compared to the benchmark, which raises concerns about its sustainability.

Read More

Is Lineage Cell Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Lineage Cell Therapeutics, Inc. shows a bullish technical trend, supported by positive MACD and moving averages, despite a bearish weekly RSI, and has significantly outperformed the S&P 500 with a year-to-date return of 208.46%.

As of 10 September 2025, the technical trend for Lineage Cell Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from the Bollinger Bands and daily moving averages. However, the weekly RSI remains bearish, indicating some short-term weakness. The company has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 208.46% compared to the S&P 500's 12.22%. Overall, the current technical stance is bullish, with strong indicators driving this sentiment.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 283 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.85

stock-summary
Return on Equity

-36.40%

stock-summary
Price to Book

5.85

Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Jun 2025)
Net Profit:
-30 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
45.0%
0%
45.0%
6 Months
164.36%
0%
164.36%
1 Year
233.27%
0%
233.27%
2 Years
74.0%
0%
74.0%
3 Years
16.0%
0%
16.0%
4 Years
-14.71%
0%
-14.71%
5 Years
8.07%
0%
8.07%

Lineage Cell Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Lineage Cell Therapeutics Hits New 52-Week High of $2.09

Lineage Cell Therapeutics Hits New 52-Week High of $2.09

Lineage Cell Therapeutics, Inc. achieved a new 52-week high of USD 2.09 on November 3, 2025, reflecting a significant increase from its low of USD 0.37. With a market cap of USD 283 million, the company operates in the Pharmaceuticals & Biotechnology sector, showcasing notable performance metrics.

Read More
Lineage Cell Therapeutics Hits New 52-Week High of $1.95

Lineage Cell Therapeutics Hits New 52-Week High of $1.95

Lineage Cell Therapeutics, Inc. achieved a new 52-week high of USD 1.95 on October 31, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 144.59% increase over the past year, despite being loss-making and not offering dividends.

Read More
Lineage Cell Therapeutics Hits New 52-Week High of $1.87

Lineage Cell Therapeutics Hits New 52-Week High of $1.87

Lineage Cell Therapeutics, Inc. achieved a new 52-week high of USD 1.87 on October 30, 2025, reflecting strong performance in the pharmaceuticals and biotechnology sector. The company has seen a 134.39% increase over the past year, despite being loss-making and lacking a dividend yield.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
52.80%
EBIT Growth (5y)
5.37%
EBIT to Interest (avg)
-28.88
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.59
Sales to Capital Employed (avg)
0.14
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
58.70%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.95
EV to EBIT
-5.04
EV to EBITDA
-5.19
EV to Capital Employed
3.33
EV to Sales
11.24
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-66.01%
ROE (Latest)
-26.06%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 23 Schemes (10.83%)

Foreign Institutions

Held by 29 Foreign Institutions (1.25%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 86.67% vs -48.28% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -641.46% vs -24.24% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.80",
          "val2": "1.50",
          "chgp": "86.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.80",
          "val2": "-6.30",
          "chgp": "23.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-27.60",
          "val2": "2.30",
          "chgp": "-1,300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-30.40",
          "val2": "-4.10",
          "chgp": "-641.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,786.60%",
          "val2": "-4,330.90%",
          "chgp": "254.43%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 6.74% vs -39.46% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 13.49% vs 18.56% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9.50",
          "val2": "8.90",
          "chgp": "6.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-20.90",
          "val2": "-24.00",
          "chgp": "12.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.10",
          "val2": "-0.20",
          "chgp": "1,150.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.60",
          "val2": "-21.50",
          "chgp": "13.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,261.10%",
          "val2": "-2,765.00%",
          "chgp": "50.39%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
2.80
1.50
86.67%
Operating Profit (PBDIT) excl Other Income
-4.80
-6.30
23.81%
Interest
0.00
0.00
Exceptional Items
-27.60
2.30
-1,300.00%
Consolidate Net Profit
-30.40
-4.10
-641.46%
Operating Profit Margin (Excl OI)
-1,786.60%
-4,330.90%
254.43%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 86.67% vs -48.28% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -641.46% vs -24.24% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
9.50
8.90
6.74%
Operating Profit (PBDIT) excl Other Income
-20.90
-24.00
12.92%
Interest
0.00
0.00
Exceptional Items
2.10
-0.20
1,150.00%
Consolidate Net Profit
-18.60
-21.50
13.49%
Operating Profit Margin (Excl OI)
-2,261.10%
-2,765.00%
50.39%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 6.74% vs -39.46% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 13.49% vs 18.56% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Lineage Cell Therapeutics, Inc. stock-summary
stock-summary
Lineage Cell Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Lineage Cell Therapeutics, Inc., formerly BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Company is focused on developing cell therapies. It programs are based on its cell-based therapy platform. It is focused on developing treatments for conditions, including age-related degenerative diseases and other serious medical conditions. Its pipeline includes OpRegen, OPC1 and VAC2. OpRegen product candidate is a cell replacement therapy. OpRegen is comprised of retinal pigment epithelium cells and is being tested for the treatment of advanced dry age-related macular degeneration (dry AMD) with geographic atrophy. OPC1 is a cell replacement therapy comprised of oligodendrocyte progenitor cells. OPC1 is being developed for the treatment of acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy comprised of mature, antigen-presenting dendritic cells. VAC2 is being developed for non-small cell lung cancer (NSCLC).
Company Coordinates stock-summary
Company Details
2173 Salk Ave Ste 200 , CARLSBAD CA : 92008-7354
stock-summary
Tel: 1 510 5213390
stock-summary
http://www.biotimeinc.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."